Anna E Koopmans1, Kimberley Ober2, Hendrikus J Dubbink2, Dion Paridaens3, Nicole C Naus4, Stephan Belunek2, Bart Krist2, Edward Post2, Ellen C Zwarthoff2, Annelies de Klein5, Robert M Verdijk2. 1. Department of Ophthalmology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 2. Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 3. The Rotterdam Eye Hospital, Rotterdam, The Netherlands. 4. Department of Ophthalmology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 5. Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
PURPOSE: Hot-spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in cutaneous and conjunctival melanoma and are exceedingly rare in uveal melanoma. No information is available on the presence of these mutations in the conjunctival melanocytic precursor lesion primary acquired melanosis (PAM). We tested a cohort of uveal and conjunctival melanomas as well as conjunctival benign and premalignant melanocytic lesions for TERT promoter mutations in order to elucidate the role of these mutations in tumor progression. METHODS: TERT promoter mutation analysis on fresh tumor DNA and DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis in 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi. RESULTS: Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas. A single TERT promoter mutation was detected in 102 uveal melanomas (1%). CONCLUSIONS: We present the second documented case of TERT promoter mutation in uveal melanoma. In comparison with other types of melanoma, TERT promoter mutations occur at extremely low frequency in uveal melanoma. TERT promoter mutations are frequent in conjunctival melanoma and occur at lower frequency in PAM with atypia but were not detected in benign conjunctival melanocytic lesions. These findings favor a pathogenetic tumor progression role for TERT promoter mutations in conjunctival melanocytic lesions. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Hot-spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in cutaneous and conjunctival melanoma and are exceedingly rare in uveal melanoma. No information is available on the presence of these mutations in the conjunctival melanocytic precursor lesion primary acquired melanosis (PAM). We tested a cohort of uveal and conjunctival melanomas as well as conjunctival benign and premalignant melanocytic lesions for TERT promoter mutations in order to elucidate the role of these mutations in tumor progression. METHODS:TERT promoter mutation analysis on fresh tumor DNA and DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis in 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi. RESULTS: Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas. A single TERT promoter mutation was detected in 102 uveal melanomas (1%). CONCLUSIONS: We present the second documented case of TERT promoter mutation in uveal melanoma. In comparison with other types of melanoma, TERT promoter mutations occur at extremely low frequency in uveal melanoma. TERT promoter mutations are frequent in conjunctival melanoma and occur at lower frequency in PAM with atypia but were not detected in benign conjunctival melanocytic lesions. These findings favor a pathogenetic tumor progression role for TERT promoter mutations in conjunctival melanocytic lesions. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Swarup S Swaminathan; Matthew G Field; David Sant; Gaofeng Wang; Anat Galor; Sander R Dubovy; J William Harbour; Carol L Karp Journal: JAMA Ophthalmol Date: 2017-12-01 Impact factor: 7.389
Authors: C Mircea S Tesileanu; Linda Dirven; Maarten M J Wijnenga; Johan A F Koekkoek; Arnaud J P E Vincent; Hendrikus J Dubbink; Peggy N Atmodimedjo; Johan M Kros; Sjoerd G van Duinen; Marion Smits; Martin J B Taphoorn; Pim J French; Martin J van den Bent Journal: Neuro Oncol Date: 2020-04-15 Impact factor: 12.300
Authors: Hendrikus J Dubbink; Peggy N Atmodimedjo; Johan M Kros; Pim J French; Marc Sanson; Ahmed Idbaih; Pieter Wesseling; Roelien Enting; Wim Spliet; Cees Tijssen; Winand N M Dinjens; Thierry Gorlia; Martin J van den Bent Journal: Neuro Oncol Date: 2015-09-09 Impact factor: 12.300
Authors: Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello Journal: Mol Cancer Res Date: 2016-03-03 Impact factor: 5.852
Authors: C Mircea S Tesileanu; Marc Sanson; Wolfgang Wick; Alba A Brandes; Paul M Clement; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Jean-Francois Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; Leland Rogers; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Myra E van Linde; Kenneth Aldape; Robert B Jenkins; Johan M Kros; Pieter Wesseling; Andreas von Deimling; Youri Hoogstrate; Iris de Heer; Peggy N Atmodimedjo; Hendrikus J Dubbink; Rutger W W Brouwer; Wilfred F J van IJcken; Kin Jip Cheung; Vassilis Golfinopoulos; Brigitta G Baumert; Thierry Gorlia; Pim J French; Martin J van den Bent Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Natasha M van Poppelen; Jolique A van Ipenburg; Quincy van den Bosch; Jolanda Vaarwater; Tom Brands; Bert Eussen; Frank Magielsen; Hendrikus J Dubbink; Dion Paridaens; Erwin Brosens; Nicole Naus; Annelies de Klein; Emine Kiliç; Robert M Verdijk Journal: Int J Mol Sci Date: 2021-05-28 Impact factor: 5.923